Drug Trial Radar · NCT07054398
Assessment of Serum Catestatin Level in Acne Vulgaris Patients
Last checked: Nov 20, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 10, 2025
Primary completion
Jan 1, 2026
Study completion Jan 10, 2026
Sponsor
- Lead sponsor
- Aswan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults. Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.
Conditions
- Acne Vulgaris
Interventions
IsotretinoinDrug
* Measure the serum levels of catestatin in patients with moderate and severe acne vulgaris versus healthy control persons. * Evaluate the effect of oral isotretinoin treatment on serum catestatin levels in patients with moderate and severe acne vulgaris.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evalaute serum level of Catestatin in acne patientTime frame: 12 weeks
- Evalaute the effect of treatment with systemic isotretinonTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aswan Unuversity Hospital
Aswān, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.